202 related articles for article (PubMed ID: 20597657)
1. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
Ambrose PG; Bhavnani SM; Ellis-Grosse EJ; Drusano GL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S103-10. PubMed ID: 20597657
[TBL] [Abstract][Full Text] [Related]
2. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
Talbot GH
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
[TBL] [Abstract][Full Text] [Related]
3. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
Laessig KA
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
[TBL] [Abstract][Full Text] [Related]
4. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia.
Kollef MH
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S29-35. PubMed ID: 20597668
[TBL] [Abstract][Full Text] [Related]
5. Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia.
Chastre J; Luyt CE
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S54-8. PubMed ID: 20597673
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
Barriere SL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
[TBL] [Abstract][Full Text] [Related]
7. Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumonia.
Bradley JS
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S136-43. PubMed ID: 20597664
[TBL] [Abstract][Full Text] [Related]
8. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design.
Niederman MS
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S12-7. PubMed ID: 20597660
[TBL] [Abstract][Full Text] [Related]
9. Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia.
Sorbello A; Komo S; Valappil T; Nambiar S
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S36-41. PubMed ID: 20597669
[TBL] [Abstract][Full Text] [Related]
10. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.
Housman ST; Kuti JL; Nicolau DP
Clin Chest Med; 2011 Sep; 32(3):439-50. PubMed ID: 21867814
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.
File TM
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S42-7. PubMed ID: 20597671
[TBL] [Abstract][Full Text] [Related]
12. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
[TBL] [Abstract][Full Text] [Related]
13. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.
Ambrose PG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S225-31. PubMed ID: 18986294
[TBL] [Abstract][Full Text] [Related]
14. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.
Michalopoulos A; Fotakis D; Virtzili S; Vletsas C; Raftopoulou S; Mastora Z; Falagas ME
Respir Med; 2008 Mar; 102(3):407-12. PubMed ID: 18060758
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial treatment of ventilator-associated pneumonia.
Park DR
Respir Care; 2005 Jul; 50(7):932-52; discussion 952-5. PubMed ID: 15972114
[TBL] [Abstract][Full Text] [Related]
16. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
18. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
; ; ; ; Spellberg B; Talbot G
Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S150-70. PubMed ID: 20597666
[No Abstract] [Full Text] [Related]
19. Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents.
Goldstein I; Chastre J; Rouby JJ
Semin Respir Crit Care Med; 2006 Feb; 27(1):82-91. PubMed ID: 16508884
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
